2022
Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsFactors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.
Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 146-146. DOI: 10.1200/jco.2020.39.28_suppl.146.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaRenal cell carcinomaStage IV renal cell carcinomaPalliative care utilizationNational Cancer DatabasePalliative careClinical factorsCare utilizationCell carcinomaStage IIITreatment-specific mannerStage III renal cell carcinomaPC utilizationMetastatic renal cell carcinomaPalliative care useDisease-specific symptomsMultivariable logistic regressionComprehensive cancer programsQuality of lifeOncological guidelinesSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusMultivariable analysisTrends in the use of administrative databases in urologic oncology: 2000 – 2019.
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 – 2019. Journal Of Clinical Oncology 2021, 39: 356-356. DOI: 10.1200/jco.2021.39.6_suppl.356.Peer-Reviewed Original ResearchNational Surgical Quality Improvement ProgramPremier Healthcare DatabaseNational Cancer DatabaseNationwide Inpatient SampleAdministrative databasesUrologic oncologySEER-MedicareSurgical Quality Improvement ProgramStudy periodEnd Results (SEER) databaseQuality Improvement ProgramRepresentative study populationComparative effectiveness researchResults databaseGenitourinary malignanciesInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeTrends in the use of administrative databases in urologic oncology: 2000–2019
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000–2019. Urologic Oncology Seminars And Original Investigations 2021, 39: 487-492. PMID: 33551250, DOI: 10.1016/j.urolonc.2021.01.014.Peer-Reviewed Original ResearchConceptsAdministrative databasesUrologic oncologyNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramPremier Healthcare DatabaseEnd Results (SEER) databaseNational Cancer DatabaseNationwide Inpatient SampleQuality Improvement ProgramRepresentative study populationComparative effectiveness researchGenitourinary malignanciesResults databaseSEER-MedicareInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeStudy period
2020
Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).
Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT). Journal Of Clinical Oncology 2020, 38: e17052-e17052. DOI: 10.1200/jco.2020.38.15_suppl.e17052.Peer-Reviewed Original ResearchNonseminomatous germ cell tumorsRetroperitoneal lymph node dissectionLymph node countOverall survivalLN countStage IPrimary retroperitoneal lymph node dissectionTesticular nonseminomatous germ cell tumorsMultivariate analysisClinical stage ILymph node dissectionNational Cancer DatabaseSingle-center studyKaplan-Meier methodGerm cell tumorsNode countPT2 diseaseNode dissectionAnalytic cohortFavorable survivalCenter studyCell tumorsCancer DatabaseTherapeutic implicationsAcademic centersAccuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsPrimary retroperitoneal lymph node dissectionCS I patientsNational Cancer DatabaseI patientsClinical stageOverall survivalClinical stagingTesticular nonseminomatous germ cell tumorsLymph node dissectionQuarter of patientsKaplan-Meier methodNodal disease burdenGerm cell tumorsUpstaging of diseaseCS1 patientsPathologic nodalPN3 diseasePrior chemotherapyNode dissectionIIA patientsMeier methodClinical outcomesTesticular cancer
2019
Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trialsTreatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses.
Sterling J, Rivera-Nunez Z, Farber N, Modi P, Radadia K, Kim S, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses. Journal Of Clinical Oncology 2019, 37: 648-648. DOI: 10.1200/jco.2019.37.7_suppl.648.Peer-Reviewed Original ResearchRenal cell carcinomaNational Cancer DatabaseCT1b patientsPartial nephrectomyCT1a patientsOpen procedureAcademic centersCT1 renal cell carcinomaUtilization of PNPrivate insuranceClinical T1a tumorsPatterns of careLower household incomeLogistic regression modelsCT1a tumorsCT1b tumorsRCC surgeryT1a tumorsClinical characteristicsCT1 tumorsT1b tumorsTreatment disparitiesImpact of regionalizationCell carcinomaAUA guidelinesFactors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma.
Radadia K, Rivera-Nunez Z, Kim S, Farber N, Sterling J, Modi P, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma. Journal Of Clinical Oncology 2019, 37: 672-672. DOI: 10.1200/jco.2019.37.7_suppl.672.Peer-Reviewed Original ResearchClinical lymph nodesLymph node dissectionRenal cell carcinomaNational Cancer DatabaseTime of surgeryNode dissectionCell carcinomaTreatment centersPositive clinical lymph nodesNonmetastatic renal cell carcinomaAmerican Urological Association guidelinesNon-metastatic patientsClinical T stageEntire study populationPreoperative imaging modalitiesLogistic regression modelsGreatest predictorClinical characteristicsNodal involvementClinical stagingLymph nodesRegional lymphadenopathyT stageOpen surgeryRenal surgery
2018
MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014
Tabakin A, Kim S, Polotti C, Rivera-Núñez Z, Sterling J, Modi P, Farber N, Radadia K, Parikh R, Goyal S, Weiss R, Kim I, Elsamra S, Singer E, Jang T. MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014. Journal Of Urology 2018, 199: e1129. DOI: 10.1016/j.juro.2018.02.2780.Peer-Reviewed Original Research
2017
Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer
Parikh R, Patel A, Kim S, Kim I, Goyal S. Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer. International Journal Of Surgery Oncology 2017, 2: e13. PMID: 29177226, PMCID: PMC5673152, DOI: 10.1097/ij9.0000000000000013.Peer-Reviewed Original ResearchLow-risk prostate cancerLow-risk prostate cancer patientsNational Cancer DatabaseProstate cancer patientsProstate cancerCancer patientsCancer DatabaseMortality rateComparative effectivenessAcademic/research centersCharlson-Deyo comorbidity scoreHigh-volume hospitalsSurgical margin statusAbove inclusion criteriaRisk of deathCase-control studyComorbidity scoreMargin statusSurgery typeBlack patientsInsurance statusOpen prostatectomyOdds ratioInclusion criteriaClinicopathologic parametersLocal Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer
Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMetastatic prostate cancerLocal therapyOverall survivalProstate cancerRadiation therapyMultivariable Cox proportional hazards modelsLower co-morbidity scoreFive-year overall survivalCox proportional hazards modelAcademic/research programCo-morbidity scoreSuperior overall survivalNode-negative statusProspective clinical trialsKaplan-Meier methodLower T stagePatterns of careProportional hazards modelPropensity-score matchingPrimary diseaseT stageMedicare insuranceGleason scoreCancer Database